Open AccessAntifungal and Antibiofilm Activities of Selective Serotonin Reuptake Inhibitors Alone and in Combination with Fluconazole
Author(s) -
Yamaç Tekintaş,
Aybala Temel,
Ayşegül Ateş,
Bayrı Eraç,
Dilek Yeşim Metin,
Süleyha Hilmioğlu Polat,
Mine Hoşgör Limoncu
Publication year - 2020
Publication title -
turkish journal of pharmaceutical sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.241
H-Index - 14
eISSN - 2148-6247
pISSN - 1304-530X
DOI - 10.4274/tjps.galenos.2019.65481
Subject(s) - biofilm , fluconazole , microbiology and biotechnology , candida glabrata , candida krusei , candida parapsilosis , candida tropicalis , broth microdilution , minimum inhibitory concentration , sertraline , corpus albicans , chemistry , pharmacology , candida albicans , antifungal , biology , antimicrobial , bacteria , antidepressant , genetics , neuroscience , hippocampus
Candida spp. are clinically important pathogens that cause difficulties for treatment by biofilm formation. Considering antifungal resistance rates and the limitations in the discovery of new antifungals, the antifungal and antibiofilm effects of various drugs used for different therapeutic purposes are becoming more important. The goal of our study was to determine the antifungal and antibiofilm effects of the selective serotonin reuptake inhibitors (SSRIs), namely sertraline (SRT), paroxetine (PRX), and fluoxetine (FLX) alone and in combination with fluconazole (FLC) against Candida spp.